health technology assessment -...
TRANSCRIPT
HEALTH TECHNOLOGY ASSESSMENT
Edmund Jessop
www.eurordis.org
¨Barcelona June 2010
2 Health technology assessment
Session outline
•Assessing benefit
•Assessing cost
•Assessing evidence
3
COSTS
HEALTH TECHNOLOGY ASSESSMENT
4
Costs
•Exercise – driving to Paris
TITRE DE LA PRESENTATION (A MODIFIER SUR LE MASQUE)
5
Cost types
•Unit and marginal costs
•Incremental costs
•Opportunity costs
•Tangible and intangible costs
HEALTH TECHNOLOGY ASSESSMENT
6
BENEFITS
HEALTH TECHNOLOGY ASSESSMENT
7
Benefits
•Survival
•Quality of life
HEALTH TECHNOLOGY ASSESSMENT
8
Assessing benefit
•Treatment X cures a fatal disease of
childhood
•Costs £100 000
•Extends life by 50 years
HEALTH TECHNOLOGY ASSESSMENT
9
Assessing benefit
•Treatment Y improves survival in a
fatal cancer
•Costs £10 000
•Extends life by 1 year
HEALTH TECHNOLOGY ASSESSMENT
10
Assessing benefit
•Treatment Y
•£10 000
•1 extra year of life
•Treatment Z
•£10 000
•1 extra year of life
BUT...
•Patient too ill to get
out of bed
HEALTH TECHNOLOGY ASSESSMENT
11
Assessing benefit
•Mobility
•Self Care – wash and dress
•Usual activities
•Pain
•Anxious or depressed
HEALTH TECHNOLOGY ASSESSMENT
12
Health state A
•No problem with mobility
•No problem with self care
•Some problems with usual activities
•Extreme pain
•Moderately depressed
HEALTH TECHNOLOGY ASSESSMENT
13
Health state B
•Some problems walking about
•Unable to wash or dress
•Some problems with usual activities
•No pain
•Not anxious or depressed
HEALTH TECHNOLOGY ASSESSMENT
14
Health state C
•Some problems walking about
•No problems washing or dressing
•Unable to do usual activities
•No pain
•Moderately depressed
TITRE DE LA PRESENTATION (A MODIFIER SUR LE MASQUE)
15
Health state D
•No problems walking about
•No problems washing or dressing
•Some problems with usual activities
•No pain
•Not anxious or depressed
HEALTH TECHNOLOGY ASSESSMENT
16
Improvement in health state
•Health state before:
•Extreme pain
•Moderately
depressed
•Some problem with
usual activity
•Health state after:
•No pain
•No depression
•Some problem with
usual activity
HEALTH TECHNOLOGY ASSESSMENT
17
Health gain
• 20 years in health state without treatment = 20 x
• 20 years in health state with treatment = 20 x
•Gain =
HEALTH TECHNOLOGY ASSESSMENT
18
Growth hormone
• Extra height as adult: valuation = 0.1
• Adult life span = 50 years
5 QALY gain
• Cost = £10 000
• £2 000 per QALY – cost is justified
HEALTH TECHNOLOGY ASSESSMENT
19
A note on ethics
•Utilitarianism
•Other ethics
HEALTH TECHNOLOGY ASSESSMENT
20
STRENGTH OF EVIDENCE
HEALTH TECHNOLOGY ASSESSMENT
21
Evidence
•Exercise – 5 scenarios
HEALTH TECHNOLOGY ASSESSMENT
22
Assessing evidence
Stories
Historic comparison
Head-to-head
HEALTH TECHNOLOGY ASSESSMENT
23
Assessing evidence
•Anecdote, case series
•Placebo effects
HEALTH TECHNOLOGY ASSESSMENT
24
Assessing evidence
•Historic comparisons
HEALTH TECHNOLOGY ASSESSMENT
25
0 6 12 18 24 30 36 42 48 54 60
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pro
po
rtio
n o
f P
atie
nts
Alive
Age (months)
0 6 12 18 24 30 36 42 48 54 60
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pro
po
rtio
n o
f P
atie
nts
Alive
Age (months)
Untreated Infants in
Natural History Study*
Infants on ERT (n=17)*
*Based on n=163 with available data
ERT in Infantile-Onset Pompe Disease:
Survival Comparison by Kaplan Meier Analysis
26
Fig. 3
Source: Neuromuscular Disorders 2007; 17:470-475 (DOI:10.1016/j.nmd.2007.03.002 )
Copyright © 2007 Terms and Conditions
27
Assessing evidence
•Trials
•Controlled trials
•Placebo controlled trials
•Randomised trials
•Double blind trials
HEALTH TECHNOLOGY ASSESSMENT
28
Assessing evidence
•Systematic review
•Meta analysis
•Problems in systematic reviews
HEALTH TECHNOLOGY ASSESSMENT
29
Assessing evidence
•Head-to-head comparison
•Modelled comparison
HEALTH TECHNOLOGY ASSESSMENT
30
A note on chance
•Effect and cost estimates:
Point estimates
Confidence intervals
HEALTH TECHNOLOGY ASSESSMENT
31
Variability: 6MWT
HEALTH TECHNOLOGY ASSESSMENT